Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

• Associate Professor of Pharmacology and Cancer Biology
• Core Faculty in Innovation & Entrepreneurship
• Member of the Duke Cancer Institute

Contact Information

• Email Address: kris.wood@duke.edu
• Websites:
  • Wood Lab

Education

• Ph.D. Massachusetts Institute of Technology, 2007
• B.S. University of Kentucky, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

• CMB 710B: Cell & Molecular Biology Module II
• CMB 710E: Cell & Molecular Biology Module V
• MOLCAN 818: Molecular Mechanisms of Oncogenesis
• PHARM 393: Research Independent Study
• PHARM 394: Research Independent Study
• PHARM 493: Research Independent Study
• PHARM 494: Research Independent Study
• PHARM 495: Research Independent Study
• PHARM 818: Molecular Mechanisms of Oncogenesis
• UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

• Locking Leukemia's Cellular Escape Hatch (Jun 7, 2022 | Pratt)
• Cancer Repair Mechanism Could Be Potential Drug Target (Mar 31, 2022 | Duke Health News)
• Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, 2019 | Pratt School of Engineering)
• From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
• Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
• Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | Duke Cancer Institute)
• The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog)
• Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)

Representative Publications

• Lin, KH; Rutter, JC; Xie, A; Killarney, ST; Vaganay, C; Benaksas, C; Ling, F; Sodaro, G; Meslin, P-A; Bassil, CF; Fenouille, N; Hoj, J; Washart, R; Ang, HX; Cerda-Smith, C; Chaintreuil, P; Jacquel, A; Auberger, P; Forget, A; Itzykson, R; Lu, M; Lin, J; Pierobon, M; Sheng, Z; Li, X; Chilkoti, A; Owzar, K; Rizzieri, DA; Pardee, TS; Benajiba, L; Petricoin, E; Puissant, A; Wood, KC, P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia., Nature Cancer (2022) [10.1038/s43018-022-00394-x] [abs].
• Wood, KC, Drivers of intrinsic resistance., Nat Chem Biol, vol 18 no. 6 (2022), pp. 579-581 [10.1038/s41589-022-00980-1] [abs].
• Zhong, Z; Harmston, N; Wood, KC; Madan, B; Virshup, DM, A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models., The Journal of Clinical Investigation, vol 132 no. 12 (2022) [10.1172/jci156305] [abs].
• Javaid, S; Schaefer, A; Goodwin, CM; Nguyen, VV; Massey, FL; Pierobon, M; Gambrell-Sanders, D; Waters, AM; Lambert, KN; Diehl, JN; Hobbs, GA; Wood, KC; Petricoin, EF; Der, CJ; Cox, AD, Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma., Mol Cancer Ther, vol 21 no. 5 (2022), pp. 762-774 [10.1158/1535-7163.MCT-21-0142] [abs].
• Ali, M; Lu, M; Ang, HX; Soderquist, RS; Eyler, CE; Hutchinson, HM; Glass, C; Bassil, CF; Lopez, OM; Kerr, DL; Falcon, CJ; Yu, HA; Hata, AN; Blakely, CM; McCoach, CE; Bivona, TG; Wood, KC, Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells., Sci Transl Med, vol 14 no. 638 (2022) [10.1126/scitranslmed.abc7480] [abs].